Drugs /

androgen receptor-directed therapy

Back to Drugs List

Overview

NCI Definition [1]:
Therapy designed to downregulate androgens by targeting of the androgen receptor and its signaling pathway.

Clinical Trials

View Clinical Trials for androgen receptor-directed therapy

Androgen receptor-directed therapy has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating androgen receptor-directed therapy, 1 is phase 3 (1 open).

FOLH1 Expression is the most frequent biomarker inclusion criterion for androgen receptor-directed therapy clinical trials.

Prostate adenocarcinoma is the most common disease being investigated in androgen receptor-directed therapy clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Androgen Receptor-Directed Therapy
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating androgen receptor-directed therapy and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ardt, androgen receptor targeted therapy
NCIT ID [1]:
C179216

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.